- Company Also Updates Findings Related to Australian Sponsored
Publication Practices From 2000-2005
PHILADELPHIA, June 4 /CNW/ - Elsevier, a leading international publisher
of scientific, technical and medical (STM) information products and services,
announced today it has moved to provide consistent internal guidelines for its
pharmaceutical services divisions when producing reprints, article
compilations or custom publications on behalf of pharmaceutical companies.
This initiative follows an internal review that was commenced when the company
became aware of a series of publications produced in Australia between the
years 2000 and 2005 that carried the name "journal of" but lacked proper
sponsor disclosures and were not in fact journals and should not have been
titled as such.
Given the issues identified in the Australasian series, the company is
acting to ensure that all of its pharmaceutical services divisions around the
globe are following consistent sponsorship practices and disclosure standards
for various article reprint products. While these pharmaceutical services
divisions frequently reprint peer reviewed articles from Elsevier, they are
managed separately from the division that publishes the company's core
collection of primary research journals.
Elsevier will review practices related to all article reprint,
compilation or custom publications and set out guidelines on content,
permission, use of imprint and repackaging to ensure that such publications
are not confused with Elsevier's core peer reviewed journals and that the
sponsorship of any publication is clearly disclosed. Elsevier expects to
complete its review and issue guidelines by June 30, 2009.
"Full disclosure should be the standard at Elsevier, and we need to
strive every day to make sure that we enforce consistent global guidelines for
sponsorship and disclosure for article reprint products," said Michael Hansen,
CEO of Elsevier Health Sciences. "I want to assure our authors, editors, and
customers that the integrity of our peer reviewed research journals has not
been compromised in any way. These guidelines will help ensure that there is
no confusion between these special compilations and our core collection of
primary research journals."
Elsevier and other STM publishers each year produce tens of thousands of
reprint products (authorized reprints of articles from original primary
journals), mostly one or two article reprints with paper covers (compilation
products), to more content rich products with reprinted peer reviewed articles
and other summaries, abstracts, case studies, conference summaries and glossy
covers (custom publications). These products are produced for pharmaceutical
companies and serve a valid and useful educational and marketing purpose for
Update on the Internal Review of Australian Sponsored Journals
Elsevier remains confident the 'Australasian Journal of' series is an
isolated practice led by former employees in a local pharmaceutical services
division. Within the 'Australasian Journal of' series, the Australasian
Journal of Bone and Joint is the only title identified as single sponsored
without proper disclosure. An additional eight "Journal of" titles were
published with ads from multiple advertisers and therefore did not call for
additional disclosure. None of these nine titles were primary research
journals and should not have been called journals. An additional 13
'Australasian Journal of' titles were registered to obtain International
Standard Serial Number (ISSN) numbers, but were never printed.
Single issues were typically distributed to between 2,000 and 10,000
general practitioners (GP) in Australia, and the company is aware of one issue
that went to 20,000 (the estimated total number of GPs in Australia).
Customized and reprint compilation publications, including the
'Australasian Journal of' series are not posted on Science Direct, Elsevier's
electronic journal platform for its peer reviewed STM journals. Also, they are
not required to be archived or retained.
Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. Working in partnership with the
global science and health communities, Elsevier's 7,000 employees in over 70
offices worldwide publish more than 2,000 journals and 1,900 new books per
year, in addition to offering a suite of innovative electronic products, such
as ScienceDirect (http://www.sciencedirect.com/), MD Consult (
http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/),
bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in
Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed
Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher
and information provider. Operating in the science and medical, legal,
education, and business-to-business sectors, Reed Elsevier provides
high-quality and flexible information solutions to users, with increasing
emphasis on the Internet as a means of delivery. Reed Elsevier's ticker
symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK, and
ENL (New York Stock Exchange).
For further information:
For further information: Tom Reller, Director, Corporate Relations,
Elsevier, (212) 462-1912, T.Reller@Elsevier.com